Clinical trials
Pathological Complete Response clinical trials
Below are recruiting pathological complete response clinical trials, each written for real people, not researchers. We’re tracking 26 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04293796Recruiting
Skipping breast surgery after complete response
This trial looks at whether some people with breast cancer can safely avoid breast surgery after they respond completely to treatment before surgery. If you have no remaining cancer in the tissue and lymph node tests, this study checks whether the “watch-and-wait” approach is feasible and safe.
Saint PetersburgAges 18–70 - NCT06182657Recruiting
Nasopharyngeal cancer response to induction chemotherapy
This study looks at how well nasopharyngeal cancer (NPC) responds to the first round of chemotherapy before other treatments. It aims to see if the amount of tumor shrinkage can help predict outcomes and guide future care for people with advanced NPC.
Nanchang, JiangxiAges 18 years+ - NCT06299202Recruiting
Predicting breast cancer treatment response with special mammogram
This study uses a special type of mammogram with contrast dye to see if it can predict how well breast cancer responds to chemotherapy before surgery. It's for people with HER2-positive or triple-negative breast cancer.
LyonAges 35 years+ - NCT07088354Recruiting
AI model predicts treatment response in esophageal cancer
This trial tests whether an artificial intelligence (AI) model can accurately predict if esophageal cancer will completely disappear after chemotherapy combined with immunotherapy before surgery. If successful, it could help doctors decide the best treatment plan for patients.
Wuhan, HubeiAges 18 years+ - NCT06364371Recruiting
Predicting rectal cancer treatment response using multi-omics
This trial is testing a new way to predict how well your rectal cancer will respond to treatments given before surgery. It uses advanced tests (like looking at genes and other markers) to tailor your care.
Guangzhou, GuangdongAges 18–80 - NCT04677816RecruitingPhase 2
Vitamin D for a better response to chemotherapy
This study tests whether taking high-dose vitamin D before and during chemotherapy helps eliminate more cancer before surgery in people with triple-negative breast cancer who are low in vitamin D.
Winston-Salem, North CarolinaAges 18 years+ - NCT06312137RecruitingPhase 3
Pembrolizumab with or without another drug for lung cancer after surgery
This trial tests adding a new drug (sacituzumab tirumotecan) to pembrolizumab for people with non-small cell lung cancer that did not completely disappear after initial treatment and surgery. The goal is to see if the combination works better than pembrolizumab alone.
Little Rock, ArkansasAges 18 years+ - NCT04815694Recruiting
MRI-guided radiotherapy for rectal cancer
This trial tests whether using MRI scans to guide radiotherapy can improve treatment for people with a certain type of rectal cancer. It focuses on patients whose tumors have not spread to other parts of the body and who have specific tumor features seen on MRI.
Roma, RomaAges 18 years+ - NCT06764355RecruitingPhase 2
Chemo, Immunotherapy, and Chemoradiation Before Surgery for Advanced Esophageal Cancer
This trial tests a combination of chemotherapy, immunotherapy, and chemoradiation before surgery for people with advanced esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
TaipeiAges 18–75 - NCT05812807RecruitingPhase 3
Pembrolizumab versus monitoring after triple-negative breast cancer response
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
Birmingham, AlabamaAges 18 years+ - NCT06876714RecruitingPhase 3
Shorter vs Longer HER2 Therapy for Breast Cancer with Complete Response
This trial compares 6 months versus 12 months of HER2-targeted therapy for people with HER2+ breast cancer who had a complete response after chemo and trastuzumab. The goal is to see if a shorter treatment is just as effective.
Phoenix, ArizonaAges 18 years+ - NCT07593976RecruitingPhase 2
New PET scan to predict breast cancer treatment response
This study tests a new type of PET scan (a specialized imaging test) to see if it can predict whether chemotherapy will work for HER2-positive breast cancer before surgery. The scan uses a radioactive tracer designed to highlight HER2-positive cancer cells, helping doctors personalize your treatment plan.
RouenAges 18 years+ - NCT04018872RecruitingPhase 2
Itraconazole trial for esophageal cancer response
This Phase 2 trial tests whether itraconazole (an antifungal medicine) can help people with localized esophageal or gastroesophageal junction cancer achieve a better “pathologic complete response,” meaning no remaining cancer found after treatment. You may be considered if your cancer is in a localized/locoregional stage and you meet key safety checks.
Dallas, TexasAges 18 years+ - NCT05416164Recruiting
Testes less radiation after a complete response to medicines
This study checks whether some people with breast cancer who have no remaining cancer after medicine (neoadjuvant systemic therapy) can safely receive less radiation. It may help reduce side effects while still keeping cancer controlled.
Amsterdam, North HollandAges 18 years+ - NCT05563766RecruitingPhase 2
Itraconazole added for treatable esophageal cancer before surgery
This study tests whether adding itraconazole (an anti-fungal medicine) to standard chemo-radiation before surgery increases the chance of complete tumor response. It’s for people with esophageal (or GE junction) cancer that can be removed with curative surgery after treatment.
Palo Alto, CaliforniaAges 18 years+ - NCT05939830Recruiting
Skipping axillary lymph node surgery after treatment response
This study looks at whether some breast cancer patients can safely skip a surgery that removes lymph nodes in the armpit after their initial (pre-surgery) treatment shows the armpit is likely clear. It may reduce surgical side effects if the armpit truly responds well.
NanjingAges 18–70 - NCT06261918Recruiting
Breast cancer study: linking metabolism to tumor behavior
This study looks at how your metabolism (things like blood sugar and cholesterol) might be linked to tumor genes and growth in people with breast cancer. The goal is to find new ways to treat the disease based on your metabolic profile. You may be eligible if you have locally advanced breast cancer (Stage II–III) and are willing to share your medical records.
RomaAges 18 years+ - NCT06719414Recruiting
Using a special MRI to predict rectal cancer response to pre-surgery therapy
This trial uses a special type of MRI scan (called amide proton transfer-weighted imaging) to look at your rectal cancer before and after chemotherapy and/or radiation. The goal is to see if the scan can predict whether the cancer has completely disappeared by the time of surgery, which could help guide future treatment decisions.
Guangzhou, GuangdongAges Any age - NCT07066189Recruiting
Lifestyle, Exercise, and Nutrition for Triple-Negative Breast Cancer
This study tests whether a healthy lifestyle program (diet and exercise) can help improve the results of breast cancer treatment before surgery. It's for women with triple-negative breast cancer who are getting chemotherapy and immunotherapy.
New Haven, ConnecticutAges 18 years+ - NCT07430579Recruiting
Adebrelimab with chemo for esophageal cancer
This trial tests adding adebrelimab (an immunotherapy drug) to standard chemotherapy for people with a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this combination helps shrink tumors before surgery.
JinanAges 18–80 - NCT07006012Recruiting
Study of RGL-305 for lymphoma with minimal residual disease
This trial tests if a new treatment called RGL-305 can help people with lymphoma who still have tiny amounts of cancer cells left after previous treatment. It is for those whose disease has responded to prior therapy but is not completely gone at the genetic level.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04741997RecruitingEarly Phase 1
Adjuvant melanoma treatment guided by response to targeted drugs
This early-phase study looks at whether people with melanoma can get the “right” follow-up (extra) treatment based on how well their cancer responds after starting targeted drugs before surgery. The goal is to improve outcomes while better matching treatment to each person’s tumor response.
Tampa, FloridaAges 18 years+ - NCT05444712Recruiting
Stem cell transplant after best response in some T-cell lymphomas
This trial studies whether doing an autologous stem cell transplant (using your own stem cells) after a complete response helps people with certain T-cell lymphomas stay in remission longer. It may be an option if your lymphoma has shrunk completely and you fit the safety and testing requirements.
AmiensAges 18–70 - NCT06811844RecruitingPhase 2
Shorter chemo plus immunotherapy for advanced nasopharyngeal cancer
This trial tests a shorter course of chemotherapy combined with an immunotherapy drug (camrelizumab) for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if this approach works well while reducing treatment side effects.
Xiamen, FujianAges 18–65
Hear when a new Pathological Complete Response trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pathological complete response?
- Yes. Clin2 currently lists 26 recruiting pathological complete response studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pathological complete response trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pathological complete response trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.